Methodology: Flow Cytometry

Clinical Significance:
This panel is designed to detect residual B-ALL after therapy, and includes antibodies to CD45, kappa, lambda, CD5, CD34, CD20, CD10, CD19, and CD38.

Organ: Blood/Bone Marrow

Disease State: Precursor B-Lymphoblastic Lymphoma/Leukemia (B-ALL)

CPT Code(s): 88184 x 1, 88185 x 8, 88188 x 1. The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.

Turnaround Time: Physician will be contacted by 9:00 PM PST the day of receipt for acute/life threatening conditions; next business day for routine flow cases.

Schedule: Monday-Saturday

Specimen Requirements:
• Peripheral blood, Preferred: 3 ml in sodium heparin (green top) / Acceptable: 3 ml in EDTA (purple top) - OR - • Bone marrow aspirate, Preferred: 1-2 ml in sodium heparin (green top) / Acceptable: 1-2 ml in EDTA (purple top) - OR - • Tissue: Finely minced tissue in RPMI transport media - OR - • Body fluids: In RPMI transport media